Skip to content
Sign in
SWC 2026 FinalistGrand Final: Lunch Block

Monere Ai

Smartphone eyelid-photo AI that screens for anemia in seconds without a blood draw, aimed at low-resource care.

Lehi (Utah), United States, North AmericaHealthTech, AI anemia detection
Stage
Pre-seedAI at the core
Product
PilotPilots / LOIs
Funding raised
Undisclosedno funding
Founded
20233 years ago
Founders
3Mou, Krishanu…
Global score
3.8Grade DRank 101 of 151

Overview

AI anemia detection solution that assesses risk in a few seconds, without a blood test.

Traction

Pilots / LOIs

NiADA app (analysis of a smartphone photo of the lower eyelid) available on Google Play and Apple TestFlight; MIT Solve 2024 selection (30/2,200); no user figures or named pilot.

Market

Hemoglobin testing / anemia screening

Anemia affects a large share of women and children worldwide, especially in low- and middle-income countries, where lab haemoglobin tests are often unavailable at first contact. A no-cost, needle-free screen is valuable for primary care, maternal health and community health worker programmes, which are typically funded by governments, NGOs and insurers. Adoption requires clinical validation against lab haemoglobin and, for diagnostic claims, regulatory clearance.

Addressable market

2025
$2.8B
2030
$4.3B
+9% a year

Hemoglobin testing / anemia screening: global market from $2.81bn in 2025 to $4.28bn in 2030 (CAGR ~9%) according to The Business Research Company.

Customers

Primary-care networks, maternal-health programmes, community health workers, NGOs, telehealth platforms

Who signs the cheque

Health ministries and NGOs (programmes), telehealth/primary-care operators, insurers

Geographies

  • United States (Utah)
  • Low- and middle-income countries (target need)

Drivers

  • High anemia prevalence in women and children
  • Shift of screening to smartphones and community workers
  • Cost of lab tests in low-resource settings

Headwinds

  • No validation published beyond a paper
  • Regulatory pathway for diagnostic claims
  • Accuracy across skin tones and lighting

Global hemoglobin testing market from $2.81bn in 2025 to $4.28bn in 2030 (CAGR ~9%) according to The Business Research Company.

Scalability 7/10. Smartphone app deployable anywhere, but software medical device status requires clearance in each country.

Market source: gii.tw

Technology

Category

Mobile AI diagnostic (computer vision)

AI at the coreMachine learning / predictive

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

pilot

How it works

The NiADA app analyses a smartphone photo of the lower eyelid with AI to estimate anemia risk in seconds. A Cureus paper on AI anemia detection is linked to the co-founder.

Moat

Weak today: published methods exist; moat would come from a large, diverse validation dataset and clearances.

Differentiation

Needle-free, device-free screening vs point-of-care haemoglobin meters that need strips.

Integration points

  • Telehealth and primary-care platforms (API)
  • Maternal-health apps
  • Community health worker tools

Depends on

  • Clinical validation datasets
  • Smartphone camera variability
  • Regulatory clearance for screening claims

Use of AI

AI-based non-invasive anemia screening in a few seconds, without a blood test.

Product in detail

AI-assisted non-invasive anemia screening (technical details not published).

Business

Model
Not published; likely B2B licence per screening or per programme.
Revenue logic
Per screen or per user per year, paid by programmes or platforms.
Go-to-market
App stores (Google Play, TestFlight) and programme partnerships; MIT Solve network.

Next milestones

  1. Prospective validation vs lab haemoglobin
  2. First platform/API integration partner
  3. Grant or seed round

Key risks

  • No validation
  • No users
  • Regulatory exposure

Opportunities

5 found in the network

Concrete moves for Monere Ai inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Distribution 2
  • Co-development 1
  • Investors 2

Distribution2

A channel or customer base to reach together

Anemia screening inside an AI primary-care OS

TIBOK runs primary care via its Eva assistant across Mauritius and soon Madagascar, accepts connected-device data and photos, and already offers no-blood-test screening (SilentCheck). NiADA as an API module adds a needle-free anemia screen to every consultation, giving Monere a live multi-country deployment and validation cohort.

40%confidence

Evidence from the records

  • “SilentCheck (22 questions, no blood test, biological age, built on Framingham, IDRS and SCORED)”
  • “First white-label distributor contract signed with C-Care Madagascar (19 November 2026), going live in January 2027 with its own Malagasy-speaking agent”
  • “NiADA app (analysis of a smartphone photo of the lower eyelid)”
If it works
A paid screening module for TIBOK and a prospective validation dataset for Monere across African/Indian Ocean populations.
First step
Schedule a call with TIBOK to scope an API pilot in Madagascar with lab-haemoglobin confirmation.

Add screening to Angolan teleconsultation

TERAMED's Baika platform offers 24/7 teleconsultation and corporate employee health in Angola, where anemia is prevalent; photo-based screening adds a measurable service to remote consultations.

15%confidence

Evidence from the records

  • “24/7 teleconsultation with general practitioners”
  • “Non-invasive”
If it works
A Lusophone African deployment for Monere; differentiating feature for TERAMED.
First step
Send TERAMED an integration brief and request a pilot in its corporate health programme.

Co-development1

An integration or joint product

Prenatal anemia screening for community health workers

Anemia in pregnancy is a key risk VytalBridge's maternal monitoring targets, and its Doctor Hub prioritises patients by clinical risk with offline sync for community health workers. Embedding NiADA gives VytalBridge a risk signal and Monere an African maternal-health use case.

25%confidence

Evidence from the records

  • “VytalBridge is a maternal health monitoring platform in development (Eswatini/Botswana)”
  • “AI-based non-invasive anemia screening in a few seconds, without a blood test.”
If it works
A joint grant-fundable maternal-health package.
First step
Propose a joint grant application to a maternal-health funder.

Investors2

A fund whose thesis fits

US angel network for health AI

Robin Hood Ventures invests $0.25–0.5M at pre-seed/seed in US HealthTech and AI, matching Monere's stage, and backed network member Vytala Health, a warm intro route.

20%confidence

Evidence from the records

  • “MIT Solve selection”
  • “Too early.”
If it works
A first priced pre-seed round to fund validation.
First step
Ask Vytala Health's CEO for an intro after the validation protocol is defined.

Global health-equity accelerator

StartUp Health backs pre-seed/seed HealthTech globally and supported network member Wink Biotherapeutics; Monere's health-equity angle (MIT Solve Global Health Equity) aligns.

20%confidence

Evidence from the records

  • “MIT Solve 2024 selection (30/2,200)”
  • “Real problem”
If it works
Access to health-system pilots and investor network.
First step
Apply to StartUp Health with the MIT Solve credential and an evidence plan.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

New York health-innovation company (since 2011) backing 500+ health founders in Moonshot communities: diagnostics, treatments, type 1 diabetes, Alzheimer's.

Blood-free anemia screening from a smartphone photo: a low-cost diagnostic with global reach, fitting the diagnostics moonshot.

55%confidence

Evidence from the records

  • “AI anemia detection”
  • “assesses risk in a few seconds, without a blood test”
Intro path
Wink Biotherapeutics founders (StartUp Health portfolio).
First step
Apply to the diagnostics Moonshot community.

San Francisco pre-seed firm (Charles Hudson, $250M+ AUM, 500+ companies) backing people over product, often before traction.

US pre-seed AI anemia screening from a phone photo: an AI-driven healthcare wedge at idea-to-pilot stage, exactly where Precursor writes first cheques.

50%confidence

Evidence from the records

  • “People over product, from idea stage with no traction requirement; AI a major focus across sectors.”
  • “AI anemia detection”
Intro path
GreenIRR founder (Precursor portfolio).
First step
Pitch Monere's founder story and screening market size to a Precursor principal.

Global accelerator (since 2006) investing ~$220K in founders through vertical and city programmes; alumni include Twilio, SendGrid, DigitalOcean.

Smartphone anemia screening at pre-seed: health vertical fit with a scalable AI product.

45%confidence

Evidence from the records

  • “AI anemia detection”
  • “Pre-seed”
Intro path
Monte Caldera founders (Techstars alumni).
First step
Apply to a Techstars health programme.

Boston fund investing only in PharmStars accelerator graduates: pharma-ready digital health, first 12 deals in rare-disease digital health.

Smartphone anemia-risk detection fits pharma use cases (iron therapies, oncology support). Pre-seed with an MIT Solve selection but no named pilot.

40%confidence

Evidence from the records

  • “AI anemia detection”
  • “MIT Solve 2024 selection (30/2,200)”
First step
Encourage Monere AI to apply with a pharma-partnership hypothesis.

Korean impact-focused seed investor; co-invested in BANIQL's $1.6M seed for cleaner battery-grade nickel.

Phone-photo anemia screening without a blood test: health-access impact with mass reach at pre-seed.

35%confidence

Evidence from the records

  • “AI anemia detection”
  • “Pre-seed”
Intro path
BANIQL founders (Sopoong portfolio).
First step
Pitch Monere's impact case to Sopoong.

Temasek Trust's catalytic capital vehicle for climate and health, backing NEOCRETE's US$3.5M low-carbon concrete round.

Smartphone anemia detection (MIT Solve selection): low-cost health screening with LMIC potential. Pre-seed.

35%confidence

Evidence from the records

  • “AI anemia detection”
  • “MIT Solve 2024 selection”

US accelerator network investing $100,000 per startup through 12-week programmes across climate, health, agri, fintech and deep tech.

US pre-seed AI anemia detection — HealthTech at pre-seed in the US matches the template; validation data is the key unknown.

40%confidence

Evidence from the records

  • “"Pre-seed"”
  • “AI anemia detection”
  • “NiADA app (analysis of a smartphone photo of the lower eyelid) available on Google Play and Apple TestFlight”
Intro path
Founder-to-founder intro via Chonex (network portfolio company of gener8tor).
First step
Prepare a clinical-validation milestone and apply to a health-focused gener8tor programme.

US federal biomedical research agency funding biotech, health and medtech via SBIR and research grants (Defined Bioscience, Microvitality, Corticale).

US AI anemia detection.

35%confidence

Evidence from the records

  • “"HealthTech"”
  • “AI anemia detection”
  • “NiADA app (analysis of a smartphone photo of the lower eyelid) available on Google Play and Apple TestFlight”
Intro path
Founder-to-founder intro via Corticale, Defined Bioscience, Microvitality (network portfolio company of U.S. National Institutes of Health (NIH)).
First step
Apply SBIR.

US angel network investing at pre-seed and seed; backed Vytala Health's $805K pre-seed in medical nutrition.

US pre-seed AI anemia detection — angel-stage health.

30%confidence

Evidence from the records

  • “Vytala Health”
  • “AI anemia detection”
  • “NiADA app (analysis of a smartphone photo of the lower eyelid) available on Google Play and Apple TestFlight”
Intro path
Founder-to-founder intro via Vytala Health (network portfolio company of JumpStart NJ Angel Network).
First step
Ask Vytala for a referral.

Spanish healthcare corporate investor whose only known venture deal is dermatology AI company Legit.Health.

US AI anemia detection — HealthTech, but no Spanish link.

25%confidence

Evidence from the records

  • “"HealthTech"”
  • “AI anemia detection”
  • “NiADA app (analysis of a smartphone photo of the lower eyelid) available on Google Play and Apple TestFlight”
Intro path
Founder-to-founder intro via Legit.Health (network portfolio company of Grupo Ribera).
First step
Low priority.

US accelerator with no public profile in our data; supported maternal-health medtech Lidavex.

US pre-seed AI anemia screening — relevant to maternal health populations.

25%confidence

Evidence from the records

  • “Lidavex”
  • “AI anemia detection”
  • “NiADA app (analysis of a smartphone photo of the lower eyelid) available on Google Play and Apple TestFlight”
Intro path
Founder-to-founder intro via Lidavex (network portfolio company of Gust Accelerator).
First step
Low priority.

bioMérieux, French in-vitro diagnostics group, investing in MedTech and life sciences, including its Allergen Alert intrapreneurship spin-off.

Smartphone-photo anemia detection: non-invasive screening, but software-only versus bioMérieux's IVD lines.

20%confidence

Evidence from the records

  • “AI anemia detection”
  • “MIT Solve 2024 selection”
First step
Position as a triage layer feeding lab confirmation.

Portuguese angel vehicle backing Portuguese AI startups at pre-seed, targeting a 20-company portfolio.

AI anemia detection from a smartphone photo: AI-core health at pre-seed. US-based, so it is outside the mandate unless it sets up in Portugal.

10%confidence

Evidence from the records

  • “AI anemia detection”
  • “Pre-seed”
First step
Not actionable without a Portuguese presence.

Investment analysis

3.8D

Grade D

Rank 101 of 151

Disruption6.0/10
Business model2.0/10
Market4.0/10
Risk(lower is better)8.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Too early.

Disruption

6/10

Anemia detection from an eyelid photo: new approach.

Business model

2/10

App in testing, no named pilot.

Market

4/10

TAM hemoglobin testing / anemia screening ~$2.81bn (base 4), medium scalability 7/10 (0), no proven international expansion (0) → 4/10.

Risk

8/10

Lower is better

High risk: clinical and regulatory validation.

Strengths

  • MIT Solve selection
  • Non-invasive

Risks

  • No validation
  • No users

Funding

Undisclosed, no funding
  1. 2024

    prize / program (MIT Solve Global Health Equity Challenge, 30 selected out of 2,200)not disclosed

    MIT Solve

Amount used in the study. No equity funding round; MIT Solve support not quantified.

Note. no public equity funding round found (MIT Solve support 2024)

Country/city added (Lehi, Utah, USA), founding year 2023, technology detail (NiADA app, eyelid photo). SWC Utah qualification (StartFEST 2026) not confirmed by a public source.

Team

  • Mou Nandi

    Cofounder & CEO

    Engineer with experience at several startups and in healthcare; student in the Master of Business Creation (University of Utah); launched the NiADA app (Dec. 2023); Utah Business '30 Women to Watch' 2025.

  • Krishanu Banerjee

    Cofounder & CDO

    Corresponding author of a Cureus paper on AI anemia detection (Crunchbase lists him as CDO).

  • Jhuma Nandi

    Cofounder & CMO (Chief Medical Officer according to some sources)

    Listed as CMO & cofounder on Crunchbase.

Sources

Identification confidence
medium
Founding year: 2023
2023 (village.ai; 1st version of NiADA in Dec. 2023)
  1. 1monere.ai/
  2. 2lassonde.utah.edu/monere-transforming-anemia-detection-with-ai/
  3. 3village.ai/company/monere-corp
  4. 4crunchbase.com/person/jhuma-nandi

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet